Corient Private Wealth
PRCT icon

Corient Private Wealth’s Procept Biorobotics PRCT Stock Holding History

Corient Private Wealth’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Buy
108,455
+51,336
+90% +$1.29M ﹤0.01% 1265
2026
Q1 		$1.43M Buy
+57,119
New +$1.61M ﹤0.01% 1445
2025
Q4 		– Sell
-6,251
Closed -$223K – 2757
2025
Q3 		$223K Buy
6,251
+321
+5% +$14.7K ﹤0.01% 2298
2025
Q2 		$342K Sell
5,930
-38
-0.6% -$2.15K ﹤0.01% 1922
2025
Q1 		$348K Buy
5,968
+137
+2% +$9.35K ﹤0.01% 1779
2024
Q4 		$470K Buy
5,831
+109
+2% +$9.31K ﹤0.01% 1659
2024
Q3 		$458K Buy
5,722
+372
+7% +$26.4K ﹤0.01% 1788
2024
Q2 		$327K Sell
5,350
-475
-8% -$28.3K ﹤0.01% 1855
2024
Q1 		$288K Buy
+5,825
New +$277K ﹤0.01% 1916

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Corient Private Wealth's PRCT Position: Q2 2026 in Review

Corient Private Wealth increased its Procept Biorobotics (PRCT) stake by 90% in Q2 2026, buying an estimated $1.29M and bringing the position to 108,455 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1265.

Corient Private Wealth first reported a position in PRCT in Q1 2024 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Corient Private Wealth held 108,455 shares of Procept Biorobotics worth $2.45M as of Q2 2026.
  • Corient Private Wealth bought 51,336 Procept Biorobotics shares in Q2 2026, an estimated $1.29M.
  • Procept Biorobotics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1265 holding.
  • Corient Private Wealth first reported a position in Procept Biorobotics in Q1 2024 and has held it in 9 quarters since.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.